Breast Cancer: Specific Situations
Brustkrebs: Spezielle Situationen

- **Versions 2005-2017:**
  Dall / Fehm / Fersis / Friedrich / Gerber / Göhring / Harbeck / Huober / Janni / Loibl / Lück / Lux / Maass / Mundhenke / Oberhoff / Rody / Scharl / Schütz / Schneeweiss / Sinn / Solomayer / Thomssen

- **Versions 2018:**
  Harbeck / Rody
Breast Cancer: Specific Situations

- Young patients
- Pregnancy- and breast-feeding-associated BC
- Elderly patients
- Male patients
- Inflammatory BC
- Occult Breast Cancer (Cancer of unknown primary – axillary CUP)
- Paget’s disease
- Malignant and Borderline Phyllodes Tumor
- Angiosarcoma
- Breast Implant-Associated Anaplastic Large-Cell Lymphoma (BIA-ALCL)
- Metaplastic breast cancer
Breast Cancer in Young Women ≤ 35 Years

- Aggressive biological behavior with worse prognosis: 2a B
- Surgery like patients ≥ 35 y: 2b B
- Guidelines adapted (neo-)adjuvant systemic treatment (see chapters there): 1b A ++
- GnRHa as ovarian protection (see chapter gyn. problems): 1a B +
- Genetic and fertility counseling: 2b B ++
- Contraception counseling: 2b B ++
### Breast Cancer During Pregnancy* or Breast Feeding – Diagnostics and Surgery

- **Breast imaging & biopsy like in non-pregnant**
  - **Oxford**
    - LoE: 4
    - GR: C
    - AGO: ++

- **Staging if indicated (Bone scan after delivery)**
  - **Oxford**
    - LoE: 5
    - GR: D
    - AGO: +

- **Full body MRI (without contrast agent)**
  - **Oxford**
    - LoE: 4
    - GR: C
    - AGO: +/-

- **Surgery like in non-pregnant patients**
  - **Oxford**
    - LoE: 4
    - GR: C
    - AGO: ++

- **Sentinel node excision (technetium only)**
  - **Oxford**
    - LoE: 4
    - GR: C
    - AGO: +

- **SLNE during 1st trimester**
  - **Oxford**
    - LoE: 5
    - GR: D
    - AGO: +/-

  - **Sensitivity and specificity not established (during lactation); breast feeding should be avoided for 24 hrs**
    - **Oxford**
      - LoE: 4
      - GR: C
      - AGO: ++

- **Blue dye (has not been tested in pregnant animals or humans)**
  - **Oxford**
    - LoE: 4
    - GR: C
    - AGO: --

* Participation in register study recommended
Breast Cancer During Pregnancy
- (Neo-)adjuvant Therapy -

- Radiation therapy during pregnancy
- (Neo-)adjuvant chemotherapy only after first trimester (indication as in non-pregnant)
  - Anthracyclines: AC, EC
  - Taxanes
  - Platin salts (carboplatin, cisplatin)
  - MTX (e.g. CMF)
- Endocrine treatment
- HER2-neu targeted treatment
- Bisphosphonates, denosumab

<table>
<thead>
<tr>
<th>Oxford</th>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4</td>
<td>C</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>B</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>C</td>
<td>+/-</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>D</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>D</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>3a</td>
<td>C</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>D</td>
<td>-</td>
</tr>
</tbody>
</table>
Breast Cancer During Pregnancy*  
– Delivery and Breast-Feeding –

- Delivery should be postponed until sufficient fetal maturation (avoid iatrogenic prematurity)
  - Oxford: 2b C ++

- Termination of pregnancy does not improve maternal outcome
  - Oxford: 3b C

- Delivery mode like in healthy women, avoid delivery ≤3 weeks from last cycle of chemotherapy
  - Oxford: 4 C ++

- If further systemic therapy is needed after delivery, breast feeding may be contraindicated depending on drug toxicities
  - Oxford: 5 D ++

* Participation in register study recommended
Breast Cancer and Pregnancy – Family Planning –

- After breast cancer diagnosis reproductive techniques can be used to induce pregnancy
  - Oxford LoE: 5, GR: D, AGO: ++

- Success rates for getting pregnant and for delivering a child are lower in breast cancer patients in comparison to non-cancer patients
  - Oxford LoE: 5, GR: D, AGO: ++

- Breast cancer patients of reproductive age should be offered a fertility counseling before starting any kind of treatment
  - Oxford LoE: 5, GR: D, AGO: ++

- Breast cancer patients should not be advised against getting pregnant regardless of tumor’s hormone receptor status
  - Oxford LoE: 5, GR: D, AGO: ++
Pregnancy Associated Breast Cancer*: Outcome

- BC during pregnancy / lactation
  - Adequate treatment is essential
- Pregnancy and lactation after BC
  - Outcome not compromised

* Participation in register study recommended
Geriatric Assessment

- No specific algorithm is available
- Ability to tolerate treatment varies greatly („functional reserve“)
- Comprehensive geriatric assessment (CGA) describes a multidisciplinary evaluation of independent predictors of morbidity and mortality for older individuals
  - Physical, mental, and psycho-social health
  - Basic activities of daily living (dressing, bathing, meal preparation, medication management, etc.)
  - Living arrangements, social network, access to support services
- Assessment tools:
  - Charlson Comorbidity Index (widely used; good predictor over a 10-year period)
  - 12 prognostic indicators to estimate 4-year mortality risk
  - Short screening tests (more qualitative evaluation)
  - IADL (IADL = The Lawton Instrumental Activities of Daily Living Scale with 8 domains of function, that are measured), G8
  - Geriatric Prognostic Index (GPI), 3 parameters in oncological patients (psychological distress or acute disease, >3 prescribed drugs, neuropsychological problems)
Treatment for Fit Elderly Patients
(Life Expectancy > 5 yrs. and Acceptable Comorbidities)

- **Clinical geriatric assessment**

- **Treatment according to guidelines**
  - Surgery similar to „younger“ age
  - Endocrine treatment (endocrine resp.)
  - Chemotherapy (standard regimens)
    - < 70 years
    - > 70 years (especially N+, ER/PgR-)
  - Radiotherapy
  - Omit radiotherapy after BCT in low risk with endocrine treatment
  - Trastuzumab

<table>
<thead>
<tr>
<th>Oxford</th>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2b</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>2a</td>
<td>C</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>1a</td>
<td>A</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>1a</td>
<td>A</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>2a</td>
<td>C</td>
<td>+*</td>
</tr>
<tr>
<td></td>
<td>1b</td>
<td>B</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>C</td>
<td>+</td>
</tr>
</tbody>
</table>

* Study participation recommended
Treatment for Frail Patients
(Life Expectancy <5 yrs, Substantial Comorbidities)

- Reduced standard treatment

- Options extrapolated from trials in elderly:
  - No breast surgery (consider endocrine options)
  - No axillary clearing (≥ 60 y, cN0, rec.-pos)
  - No radiotherapy (≥ 65 y, pT1, pN0, rec.-pos)
  - Hypofractionated radiotherapy
  - No chemotherapy if >70 years and negative risk-benefit analysis

<table>
<thead>
<tr>
<th>Oxford</th>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2b</td>
<td>C</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>C</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>B</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>1b</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>B</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>C</td>
<td>+</td>
</tr>
</tbody>
</table>
### Male Breast Cancer: Diagnostic Work-Up and Loco-Regional Therapy

<table>
<thead>
<tr>
<th>Oxford</th>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4</td>
<td>C</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>3b</td>
<td>C</td>
<td>+/-</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>C</td>
<td>+++*</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>C</td>
<td>+*</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>B</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>C</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>GCP</td>
<td></td>
<td>++</td>
</tr>
</tbody>
</table>

- **Diagnostic work-up as in women**
  - Mammography
  - Ultrasound

- **Standard-surgery: Mastectomy**
  - BCT is an option (tumor breast relation)
  - Sentinel-node excision (SNE)

- **Radiotherapy as in women**
  (consider tumor breast relation!)

- **Genetic counselling if one additional relative affected**
  (breast/ovarian cancer)

- **Screening for 2nd malignancies according to guidelines**

* Participation in register study recommended
### Male Breast Cancer: Systemic Therapy

#### Adjuvant chemotherapy as in women

- HER2-targeted therapy

#### Endocrine therapy

- Tamoxifen
- Aromatase inhibitors (adjuvant)
- Aromatase inhibitors (metastatic BC)
- GnRHa and AI (metastatic BC)
- Fulvestrant (metastatic BC)

#### Palliative chemotherapy as in women

<table>
<thead>
<tr>
<th>Oxford</th>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2a</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>D</td>
<td>+*</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>D</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>B</td>
<td>-*</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>C</td>
<td>+/-</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>C</td>
<td>+*</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>C</td>
<td>+/-</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>C</td>
<td>++</td>
</tr>
</tbody>
</table>
## Benefit from Trimodal Treatment in Inflammatory Breast Cancer

### Median survival probability

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Median Survival Probability</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trimodal therapy</td>
<td>72 months</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Surgery alone</td>
<td>26 months</td>
<td></td>
</tr>
</tbody>
</table>

### Overall survival-probability (OS)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>10 years-OS</th>
<th>5 years-OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trimodal therapy</td>
<td>55.4%</td>
<td>37.3%</td>
</tr>
<tr>
<td>Surgery &amp; chemotherapy</td>
<td>42.9%</td>
<td>28.5%</td>
</tr>
<tr>
<td>Surgery &amp; radiotherapy</td>
<td>40.7%</td>
<td>23.5%</td>
</tr>
<tr>
<td>Surgery alone</td>
<td></td>
<td>16.5%</td>
</tr>
</tbody>
</table>

### Multivariate analysis of OS

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Hazard Ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery &amp; chemotherapy &amp; RT</td>
<td>1.00</td>
<td>-</td>
</tr>
<tr>
<td>(trimodal therapy)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surgery &amp; chemotherapy</td>
<td>1.64</td>
<td>1.46 to 1.84</td>
</tr>
<tr>
<td>Surgery &amp; radiotherapy</td>
<td>1.47</td>
<td>0.96 to 2.24</td>
</tr>
<tr>
<td>Surgery alone</td>
<td>2.28</td>
<td>1.80 to 2.89</td>
</tr>
</tbody>
</table>

### Inflammatory Breast Cancer (IBC, cT4d)

- **Invasive BC and clinical signs of inflammation** (e.g. ≥ 1/3 of the breast affected) determine stage cT4d
- **Staging**
- **Skin punch biopsy** (at least 2; detection rate < 75%)
- **Neoadjuvant chemotherapy** (regimens as in noninflammatory BC)
- **Adjuvant systemic treatment according to guidelines**
- **Mastectomy after chemotherapy**
  - Breast conserving therapy in case of pCR (individual)
  - Sentinel excision only
- **Radiotherapy (PMRT)**

<table>
<thead>
<tr>
<th>Oxford</th>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2c</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>2c</td>
<td>B</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>2c</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>2c</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>2c</td>
<td>B</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>C</td>
<td>+/-</td>
</tr>
<tr>
<td></td>
<td>3b</td>
<td>C</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>2c</td>
<td>B</td>
<td>++</td>
</tr>
</tbody>
</table>
Axillary Metastasis in Occult Breast Cancer (Cancer of Unknown Primary – Axillary CUP)

- Incidence: < 1% of metastatic axillary disease

- In > 95% occult breast cancer, < 5% other primary

- Immunhistology
  - ER-positive: 55%
  - HER2 3+: 35%
  - Triple-negative: 38%

- Nodal status:
  - 1 - 3 Ln-Met. in 48%
  - > 3 Ln-Met in 52%

- Outcome similar or better than in breast cancer with similar tumor biology and tumor stage
Axillary Metastasis in Occult Breast Cancer (Axillary CUP) Imaging Diagnostics

- **Mammography, Breast-ultrasound, Breast-MRI**
- **Exclude contralateral cancer**
- **Exclude non-breast malignancy, especially in case of TNBC** (e.g. skin, female genital tract, lung, thyroid gland, stomach)
- **Staging** (CT thorax / abdomen, thyroid scintigraphy, HNT-exam)
- **PET / PET-CT**

<table>
<thead>
<tr>
<th>Oxford</th>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mammography</td>
<td>3</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td>Exclude contralateral cancer</td>
<td>3</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td>Exclude non-breast malignancy, especially in case of TNBC (e.g. skin, female genital tract, lung, thyroid gland, stomach)</td>
<td>5</td>
<td>D</td>
<td>++</td>
</tr>
<tr>
<td>Staging (CT thorax / abdomen, thyroid scintigraphy, HNT-exam)</td>
<td>3</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td>PET / PET-CT</td>
<td>3b</td>
<td>B</td>
<td>+</td>
</tr>
</tbody>
</table>
Axillary Metastasis in Occult Breast Cancer (ex. CUP)
Pathology, molecular pathology

- ER, PgR, HER2, GATA3
- Exclusion of other primary malignancies in case of triple-negative phenotype or unusual histology, e.g. lung, female genital tract, HNT tumors, neuroendocrine ca.
- Gene expression profiling for determination or primary site (CUPprint, Pathwork, TOT, Theros CTID)
- NGS, epigenetics for determination of primary site (Panel-Sequencing, EPICup)
- Prognostic gene expression tests

<table>
<thead>
<tr>
<th>Oxford</th>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5</td>
<td>D</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>D</td>
<td>++</td>
</tr>
<tr>
<td>(CUPprint, Pathwork, TOT, Theros CTID)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NGS, epigenetics for determination of primary site (Panel-Sequencing, EPICup)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prognostic gene expression tests</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

www.ago-online.de
Axillary Metastasis in Occult Breast Cancer (Axillary CUP) Therapy

- Axillary dissection
- Mastectomy if breast MRI is negative
- (Neo-) adjuvant systemic therapy according to breast cancer guidelines (AGO)
- Breast irradiation if breast MRI is negative
- Irradiation of regional lymph nodes according to breast cancer guidelines (AGO)

<table>
<thead>
<tr>
<th>Oxford</th>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3a</td>
<td>C</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>3a</td>
<td>C</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>D</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>2c</td>
<td>B</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>3b</td>
<td>B</td>
<td>+</td>
</tr>
</tbody>
</table>
Paget’s Disease of the Breast

- Paget’s disease of the breast is characterized by an intraepidermal tumor manifestation originating in intraductal or invasive breast cancer. Isolated Paget’s disease of the nipple is more rarely seen, and less aggressive.

<table>
<thead>
<tr>
<th>Feature</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Presentation</td>
<td>Paget’s disease with invasive Ca. (37 - 58%)</td>
</tr>
<tr>
<td></td>
<td>Paget’s disease mit DCIS (30 - 63%)</td>
</tr>
<tr>
<td></td>
<td>Isolated Paget’s disease (4 - 7%)</td>
</tr>
<tr>
<td></td>
<td>Isolated Paget’s disease with invasion (rare)</td>
</tr>
<tr>
<td>IHC</td>
<td>HER2-positive (83 - 97%)</td>
</tr>
<tr>
<td></td>
<td>ER-positive (10 - 14%)</td>
</tr>
<tr>
<td></td>
<td>AR-positive (71 - 88%)</td>
</tr>
</tbody>
</table>
# Paget’s Disease of the Breast Diagnosis

- **Histological verification by skin biopsy**
- **Mammography, sonography**
- **MRI of the breast if other imaging negative**
- **Immunhistology (ER, PgR, HER2, Ck7)** to detect benign and HER2-negative cases

<table>
<thead>
<tr>
<th>Oxford</th>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>D</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>C</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>D</td>
<td>++</td>
</tr>
</tbody>
</table>
# Paget’s Disease of the Breast Therapy

<table>
<thead>
<tr>
<th>Oxford</th>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5</td>
<td>D</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>1c</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>1c</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>D</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>B</td>
<td>--</td>
</tr>
</tbody>
</table>

- **Paget’s disease with underlying disease (invasive breast cancer, DCIS)**
  - Therapy according to standard of the underlying disease
  - Surgery must achieve R0

- **Isolated Paget’s disease of the NAC:**
  - Surgery must achieve R0
  - Surgical resection only, no adjuvant radiotherapy
  - Sentinel-node excision (SNE)
Borderline and Malignant Phyllodes Tumor

- Differential diagnosis may be problematic on core biopsy
- In-Breast recurrence relatively frequently seen (10 - 30%)
- Distant metastasis relatively rare (< 10%) and almost exclusively seen in malignant phyllodes tumor.

<table>
<thead>
<tr>
<th>Feature</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grading</td>
<td>Benign PT (75%)</td>
</tr>
<tr>
<td></td>
<td>Borderline PT (16%)</td>
</tr>
<tr>
<td></td>
<td>Malignant PT (9%)</td>
</tr>
<tr>
<td>Median age on diagnosis</td>
<td>Benign PT: 39 J.</td>
</tr>
<tr>
<td></td>
<td>Borderline PT: 45 J.</td>
</tr>
<tr>
<td></td>
<td>Malignant PT: 47 J.</td>
</tr>
<tr>
<td>Local recurrence</td>
<td>Benign PT: 10 - 17%</td>
</tr>
<tr>
<td></td>
<td>Borderline PT: 14 - 25%</td>
</tr>
<tr>
<td></td>
<td>Malignant PT: 23 - 30%</td>
</tr>
</tbody>
</table>
### Borderline and Malignant Phyllodes Tumor Diagnosis

#### Mammography, sonography

Oxford: 3 C ++

#### Diagnosis on core biopsy, grading on resection specimen

Oxford: 3 C ++

#### Breast MRI

Oxford: 3 C +/-

#### Staging only malignant PT (CT thorax, skeletal system)

Oxford: 5 D ++
Borderline and Malignant Phyllodes Tumor Surgery

- R0-Excision
- SNE / Axillary dissection when cN0
- Treatment of local recurrence
  - R0 resection or simple mastectomy

<table>
<thead>
<tr>
<th>Oxford</th>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2b</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>C</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>C</td>
<td>++</td>
</tr>
</tbody>
</table>
Borderline and Malignant Phyllodes Tumor
Adjuvant Therapy

- **Adjuvant radiotherapy**
  - If $T \geq 2$ cm (BCT) or $T \geq 10$ cm (mastectomy)

- **Systemic adjuvant therapy (chemo, endocrine)**

- **Treatment of local recurrence**
  - R0 resection or simple mastectomy
  - Radiotherapy, chemotherapy after R1 resection

- **Distant metastasis (very rare)**
  - Treatment like soft tissue sarcomas

<table>
<thead>
<tr>
<th>Oxford</th>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>4</td>
<td>C</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>C</td>
<td>+/-</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>C</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>C</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>C</td>
<td>+/-</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>C</td>
<td>++</td>
</tr>
</tbody>
</table>
Sarcomas of the Breast

- Not infrequently associated with familial syndromes (Li-Fraumeni, familial adenomatous polyposis, neurofibromatosis type 1)
- Primary sarcomas: angiosarcoma, undifferentiated sarcoma, leiomyosarcoma, liposarcoma, osteosarcoma
- Secondary malignancies of the breast:
  - Radiotherapy-Associated Angiosarcoma
  - Breast Implant Associated Large-Cell Anaplastic Lymphoma (BI-ALCL)
- Rare: intramammary sarcoma metastases
- Staging: TNM (UICC) or AJCC scheme of the soft tissue sarcoma analogous to sarcoma of the breast
- Grading: Analogous to the FNCLCC system for sarcoma or according to Rosen (1988) for angiosarcomas
Primary Angiosarcoma of the Breast

- Most common primary sarcoma of the breast
- Young age (median: 24 - 46 years)
- Indistinct tumor borders
- Large tumor (median: 5 - 7 cm)
- Uncharacteristic findings on mammography and sonography
- High local recurrence risk, even after mastectomy
- More unfavorable prognosis than other primary sarcoma of the breast
Primary Angiosarcoma of the Breast*

**Diagnosis**

- Mammography, sonography to determine extent of disease
- Preoperative MRI to determine the extent of disease
- Diagnosis by core biopsy
- Diagnosis by FNB
- Staging (CT thorax & abd.; angiosarcoma: MRI brain)
- Prognostic factors: size, grade, margins

<table>
<thead>
<tr>
<th>Oxford</th>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3a</td>
<td>C</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>3a</td>
<td>C</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>3a</td>
<td>C</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>3a</td>
<td>C</td>
<td>--</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>D</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>3a</td>
<td>C</td>
<td>++</td>
</tr>
</tbody>
</table>

* Therapy in specialized centers recommended
Primary Angiosarcoma of the Breast*
Therapy

- Surgery with wide clear margins, mostly as mastectomy
  - Breast-conserving therapy
- SNB or axillary dissection if cN0
- Adjuvant chemotherapy (anthracycline/taxane-based)
- Adjuvant radiotherapy if high risk (size > 5 cm, R1)

Oxford

<table>
<thead>
<tr>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td>3a</td>
<td>C</td>
<td>++</td>
</tr>
<tr>
<td>3a</td>
<td>C</td>
<td>-</td>
</tr>
<tr>
<td>3a</td>
<td>C</td>
<td>--</td>
</tr>
<tr>
<td>4</td>
<td>C</td>
<td>+/-</td>
</tr>
</tbody>
</table>

* Therapy in specialized centres recommended
Secondary (Radiotherapy-associated) Angiosarcoma of the Breast

- Cumulative incidence of radiotherapy-associated sarcoma: 3.2 per 1,000 after 15 years

- Clinical presentation
  - > 5 years after BCT or mastectomy with irradiation
  - usually intracutaneously or subcutaneously in the irradiation area with livid discoloration
  - multiple foci
  - most often in advanced stages (II - III)
  - metastasis mostly pulmonary
  - lymph node metastasis possible

- Prognosis is more unfavorable than in non-radiotherapy-associated sarcoma
- Survival after 5 years: 15%
Secondary Angiosarcoma of the Breast Therapy

- Secondary mastectomy
- Adjuvant chemotherapy (anthracycline/taxane-based)
- Adjuvant radiotherapy if high risk (size > 5 cm, R1)
- Regional hyperthermia (to improve local control) plus chemotherapy and/or radiotherapy

<table>
<thead>
<tr>
<th>Oxford</th>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>3a</td>
<td>C</td>
<td>++</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>B</td>
<td>+/-</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>B</td>
<td>+/-</td>
</tr>
<tr>
<td></td>
<td>2b</td>
<td>B</td>
<td>+/-</td>
</tr>
</tbody>
</table>
Angiosarcoma of the Breast
Treatment of Local Recurrence and Metastases

Treatment of Local Recurrence:
- R0 resection
- Adjuvant radiotherapy for high risk patients (tumor size > 5 cm, R1)

Distant Metastases / Unresectable Tumors:
- Treatment like soft tissue sarcomas
- Paclitaxel weekly / liposomal doxorubicin (in angiosarcoma)
- Antiangiogenic treatment (e.g. in angiosarcoma)
Breast Implant-Associated Anaplastic Large-Cell Lymphoma (BIA-ALCL)

- Rare, estimated annual incidence <1 per 100,000 women with implants (median age 54 years)
- Occurrence predominantly of textured implants
- 5-year OAS 89%
- Interval for lymphoma diagnosis: 8 years (median)
- Clinical presentation
  - Effusion only (60%)
  - Mass only (17%)
  - Effusion and mass (20%)
- Histological: CD30+/ALK-T cell lymphoma
- Reporting obligation as SAE according to § 3 MPSV to the BfArM
Breast Implant-Associated Anaplastic Large-Cell Lymphoma (BIA-ALCL) – Diagnosis –

- Sonography (for newly occurring seromas 1 year after implant placement, tumor mass)  
  Oxford: 5 D ++

- Breast MRI on confirmation of the diagnosis  
  Oxford: 5 D ++

- Nodal status, PET-CT, bone marrow biopsy  
  Oxford: 5 D ++

- Cytology of effusion (for newly occurring seromas 1 year after implant placement)
  with requisition “r/o BIA-ALCL”  
  Oxford: 5 D ++

- Lymphoma diagnosis on resection specimen and histological staging (acc. to Clemens 2016)  
  Oxford: 5 D ++

- Documentation of the implant (manufacturer, size, filling, surface, batch number)  
  Oxford: 5 D ++
Breast Implant-Associated Anaplastic Large-Cell Lymphoma (BIA-ALCL) – Treatment –

- **Implant removal and complete capsulectomy including tumor removal**
  - Oxford: 3a C ++

- **Removal of suspicious lymph nodes, no routine sentinel-node biopsy, no axillary dissection**
  - Oxford: 4 D ++

- **Polychemotherapy (e.g., CHOP) when extracapsular tumor infiltration**
  - Oxford: 4 D +

- **Radiation for unresectable tumors or R1**
  - Oxford: 5 D +/-

- **Reconstruction after 1 year disease-free interval**
  - Oxford: 5 D +
Breast Implant-Associated Anaplastic Large-Cell Lymphoma (BIA-ALCL)
- Summary of the Management (acc. to Noah 2017) -

Periprosthetic seroma or tumor mass > 1 year after implant placement

Exclude trauma or infection

Ultrasound / sonography

Seroma: aspiration and cytology (when suspicious: CD30-IHC)

Suspicious

+ALCL

Operative exploration with biopsy of the capsule

Tumor mass

Tumor board discussion

Confirmed ALCL cases

Tumor board discussion

Complete operative capsulectomy, tumor excision according to oncological standards Lymph node removal in case of suspicion, no new implants, possibly also contralaterally

Complete Resection R0

R1 or positive lymph nodes

Clinical follow-up. Ultrasound and CT every 6 months for 2 years, then annually for 5 years

Chemotherapy; CHOP, possibly immunotherapy

+/-

Radiatiotherapy

www.ago-online.de
Metaplastic Breast Cancer

- Imaging and histology for diagnosis according to standard
  - Oxford: LoE 5, GR D, AGO ++

- Staging including chest and abdominal CT (hematogenous metastasis)
  - Oxford: LoE 4, GR C, AGO ++

- Surgical treatment according to standard (more often MRM necessary due to advanced tumor stage, RR > 3 cm)
  - SNB
    - Oxford: LoE 4, GR C, AGO +
  - Adjuvant chemotherapy (tumors more chemoresistant)
    - Oxford: LoE 4, GR C, AGO +
  - Adjuvant endocrine standard therapy
    - Oxford: LoE 4, GR C, AGO +/-
  - Adjuvant standard radiotherapy
    - Oxford: LoE 4, GR C, AGO +
Metaplastic Breast Cancer

**Incidence:** 0.2-5 % of all breast cancers (1)

**Histology:** epithelial and mesenchymal components with two to three different components within a tumor; high proliferation rate

**Subtypes:** according to WHO (4)

- Metaplastic carcinoma of no special type
- Low-grade adenosquamous carcinoma
- Fibromatosis-like carcinoma
- Squamous cell carcinoma
- Spindle cell carcinoma
- Metaplastic carcinoma with mesenchymal differentiation
- Chondroid differentiation
- Osseous differentiation
- Other types of mesenchymal differentiation
- Mixed metaplastic carcinoma
- Myoepithelial carcinoma

**Molecular biology:**
- > 90 % ER-, PR-, HER2-
- ~ 70 % overexpression of HER1, CK 5/6-expression (stem-cell-like and BRCA-like) (2)
- Molecular profile mostly basal-like (3)
- Frequent mutations in PIK3CA and PTEN (mTOR-overactivity)

**Clinical features:**
- Large tumors at diagnosis (> 5 cm)
- Frequent hematogenous metastases; nodal involvement in ~ 20 % (no nodal involvement in spindle cell carcinoma carcinosarcoma)
- Poor clinical course compared to TNBC
- Impaired prognosis in asian women (MRM more frequently, poor grading, more often squamous cell carcinoma, spindle cell carcinoma less frequent)